GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (AMEX:AIM) » Definitions » Asset Turnover

AIM ImmunoTech (AIM ImmunoTech) Asset Turnover : 0.00 (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is AIM ImmunoTech Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. AIM ImmunoTech's Revenue for the three months ended in Dec. 2023 was $0.07 Mil. AIM ImmunoTech's Total Assets for the quarter that ended in Dec. 2023 was $23.62 Mil. Therefore, AIM ImmunoTech's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. AIM ImmunoTech's annualized ROE % for the quarter that ended in Dec. 2023 was -306.40%. It is also linked to ROA % through Du Pont Formula. AIM ImmunoTech's annualized ROA % for the quarter that ended in Dec. 2023 was -212.96%.


AIM ImmunoTech Asset Turnover Historical Data

The historical data trend for AIM ImmunoTech's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Asset Turnover Chart

AIM ImmunoTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 - - - 0.01

AIM ImmunoTech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AIM ImmunoTech's Asset Turnover

For the Biotechnology subindustry, AIM ImmunoTech's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Asset Turnover distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Asset Turnover falls into.



AIM ImmunoTech Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

AIM ImmunoTech's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0.202/( (40.488+19.381)/ 2 )
=0.202/29.9345
=0.01

AIM ImmunoTech's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0.065/( (27.861+19.381)/ 2 )
=0.065/23.621
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


AIM ImmunoTech  (AMEX:AIM) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

AIM ImmunoTech's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-50.304/16.418
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-50.304 / 0.26)*(0.26 / 23.621)*(23.621/ 16.418)
=Net Margin %*Asset Turnover*Equity Multiplier
=-19347.69 %*0.011*1.4387
=ROA %*Equity Multiplier
=-212.96 %*1.4387
=-306.40 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

AIM ImmunoTech's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-50.304/23.621
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-50.304 / 0.26)*(0.26 / 23.621)
=Net Margin %*Asset Turnover
=-19347.69 %*0.011
=-212.96 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


AIM ImmunoTech Asset Turnover Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM ImmunoTech (AIM ImmunoTech) Business Description

Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Executives
Thomas K. Equels director, officer: Vice Chairman of Board 2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
Nancy Bryan director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Stewart Appelrouth director 2117 SW HIGHWAY 484, OCALA FL 34473
Rodino Peter W. Iii director 2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
Ellen M Lintal officer: CFO 2117 SW HWY 484, OCALA FL 34473
William M Mitchell director 2117 SW HWY 484, OCALA FL 34473
Wayne S. Springate officer: VP of Operations 600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
David R Strayer other: Medical Director 600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Adam Pascale officer: CFO 600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Ralph Christopher Cavalli officer: VP, Quality Control 510 MURDOCH ROAD, PHILADELPHIA PA 19119
Russel J Lander officer: VP of Process/QualityAssurance 784 BAEDER ROAD, JENKINTOWN PA 19046
Robert Iv Dickey officer: Senior Vice President 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bernhardt Charles Thomas Iii officer: CFO 23 BIRCH ROAD, MALVERN PA 19355
Steven D Spence director 250 EAST 54TH STREET APARTMENT 36C, NEW YORK NY 10022
Anthony Bonelli officer: President & COO P.O. BOX 521, NEW VERNON NJ 07976

AIM ImmunoTech (AIM ImmunoTech) Headlines

From GuruFocus

AIM ImmunoTech Added to Russell Microcap(R) Index

By ACCESSWIRE ACCESSWIRE 06-29-2020

Could Insider Buying Signal that AIM ImmunoTech Inc Is Undervalued?

By GuruFocus Research GuruFocus Editor 01-04-2023